import{r as j,j as e,R as De,b as Ae,c as Re,d as O,e as Te}from"./index-CNAMaLj7.js";import{W as Je,X as Le,Y as ye,Z as w,$ as L,a0 as K,a1 as _e,a2 as ce,a3 as J,a4 as E,a5 as k,a6 as W,a7 as ge,a8 as Ne,S as We,V as ne,U as Ee}from"./index-BTsPUAKc.js";import{F as xe,I as Fe,t as Ge,p as Oe,q as Ke,s as He}from"./Table-Bw-jFpql.js";import"./AntdIcon-DXb-ugYL.js";import"./FolderOpenOutlined-De1L9ALG.js";function be(n=null){const o=j.createContext(n);return[({children:r,value:s})=>e.jsx(o.Provider,{value:s,children:r}),()=>j.useContext(o)]}function Ve(n="mantine-"){return`${n}${Math.random().toString(36).slice(2,11)}`}const qe=De.useId||(()=>{});function $e(){const n=qe();return n?`mantine-${n.replace(/:/g,"")}`:""}function ve(n){const o=$e(),[t,i]=j.useState(o);return Ae(()=>{i(Ve())},[]),typeof n=="string"?n:typeof window>"u"?o:t}function je({value:n,defaultValue:o,finalValue:t,onChange:i=()=>{}}){const[r,s]=j.useState(o!==void 0?o:t),h=(d,...c)=>{s(d),i?.(d,...c)};return n!==void 0?[n,i,!0]:[r,h,!1]}function Ze({classNames:n,styles:o,props:t,stylesCtx:i}){const r=Re();return{resolvedClassNames:Le({theme:r,classNames:n,props:t,stylesCtx:i||void 0}),resolvedStyles:Je({theme:r,styles:o,props:t,stylesCtx:i||void 0})}}const Se=j.forwardRef(({size:n="var(--cb-icon-size, 70%)",style:o,...t},i)=>e.jsx("svg",{viewBox:"0 0 15 15",fill:"none",xmlns:"http://www.w3.org/2000/svg",style:{...o,width:n,height:n},ref:i,...t,children:e.jsx("path",{d:"M11.7816 4.03157C12.0062 3.80702 12.0062 3.44295 11.7816 3.2184C11.5571 2.99385 11.193 2.99385 10.9685 3.2184L7.50005 6.68682L4.03164 3.2184C3.80708 2.99385 3.44301 2.99385 3.21846 3.2184C2.99391 3.44295 2.99391 3.80702 3.21846 4.03157L6.68688 7.49999L3.21846 10.9684C2.99391 11.193 2.99391 11.557 3.21846 11.7816C3.44301 12.0061 3.80708 12.0061 4.03164 11.7816L7.50005 8.31316L10.9685 11.7816C11.193 12.0061 11.5571 12.0061 11.7816 11.7816C12.0062 11.557 12.0062 11.193 11.7816 10.9684L8.31322 7.49999L11.7816 4.03157Z",fill:"currentColor",fillRule:"evenodd",clipRule:"evenodd"})}));Se.displayName="@mantine/core/CloseIcon";var Ce={root:"m_86a44da5","root--subtle":"m_220c80f2"};const Ye={variant:"subtle"},Ue=K((n,{size:o,radius:t,iconSize:i})=>({root:{"--cb-size":J(o,"cb-size"),"--cb-radius":t===void 0?void 0:ce(t),"--cb-icon-size":O(i)}})),pe=ye((n,o)=>{const t=w("CloseButton",Ye,n),{iconSize:i,children:r,vars:s,radius:h,className:d,classNames:c,style:f,styles:l,unstyled:a,"data-disabled":p,disabled:u,variant:x,icon:m,mod:y,attributes:b,__staticSelector:S,...v}=t,I=L({name:S||"CloseButton",props:t,className:d,style:f,classes:Ce,classNames:c,styles:l,unstyled:a,attributes:b,vars:s,varsResolver:Ue});return e.jsxs(_e,{ref:o,...v,unstyled:a,variant:x,disabled:u,mod:[{disabled:u||p},y],...I("root",{variant:x,active:!u&&!p}),children:[m||e.jsx(Se,{}),r]})});pe.classes=Ce;pe.displayName="@mantine/core/CloseButton";const[Qe,Xe]=be({size:"sm"}),Me=E((n,o)=>{const t=w("InputClearButton",null,n),{size:i,variant:r,vars:s,classNames:h,styles:d,...c}=t,f=Xe(),{resolvedClassNames:l,resolvedStyles:a}=Ze({classNames:h,styles:d,props:t});return e.jsx(pe,{variant:r||"transparent",ref:o,size:i||f?.size||"sm",classNames:l,styles:a,__staticSelector:"InputClearButton",style:{pointerEvents:"all",background:"var(--input-bg)",...c.style},...c})});Me.displayName="@mantine/core/InputClearButton";const eo={xs:7,sm:8,md:10,lg:12,xl:15};function oo({__clearable:n,__clearSection:o,rightSection:t,__defaultRightSection:i,size:r="sm"}){const s=n&&o;return s&&(t||i)?e.jsxs("div",{"data-combined-clear-section":!0,style:{display:"flex",gap:2,alignItems:"center",paddingInlineEnd:eo[r]},children:[s,t||i]}):t===null?null:t||s||i}const[to,oe]=be({offsetBottom:!1,offsetTop:!1,describedBy:void 0,getStyles:null,inputId:void 0,labelId:void 0});var z={wrapper:"m_6c018570",input:"m_8fb7ebe7",section:"m_82577fc2",placeholder:"m_88bacfd0",root:"m_46b77525",label:"m_8fdc1311",required:"m_78a94662",error:"m_8f816625",description:"m_fe47ce59"};const no=K((n,{size:o})=>({description:{"--input-description-size":o===void 0?void 0:`calc(${W(o)} - ${O(2)})`}})),ie=E((n,o)=>{const t=w("InputDescription",null,n),{classNames:i,className:r,style:s,styles:h,unstyled:d,vars:c,size:f,__staticSelector:l,__inheritStyles:a=!0,attributes:p,variant:u,...x}=w("InputDescription",null,t),m=oe(),y=L({name:["InputWrapper",l],props:t,classes:z,className:r,style:s,classNames:i,styles:h,unstyled:d,attributes:p,rootSelector:"description",vars:c,varsResolver:no}),b=a&&m?.getStyles||y;return e.jsx(k,{component:"p",ref:o,variant:u,size:f,...b("description",m?.getStyles?{className:r,style:s}:void 0),...x})});ie.classes=z;ie.displayName="@mantine/core/InputDescription";const io=K((n,{size:o})=>({error:{"--input-error-size":o===void 0?void 0:`calc(${W(o)} - ${O(2)})`}})),ae=E((n,o)=>{const t=w("InputError",null,n),{classNames:i,className:r,style:s,styles:h,unstyled:d,vars:c,size:f,attributes:l,__staticSelector:a,__inheritStyles:p=!0,variant:u,...x}=t,m=L({name:["InputWrapper",a],props:t,classes:z,className:r,style:s,classNames:i,styles:h,unstyled:d,attributes:l,rootSelector:"error",vars:c,varsResolver:io}),y=oe(),b=p&&y?.getStyles||m;return e.jsx(k,{component:"p",ref:o,variant:u,size:f,...b("error",y?.getStyles?{className:r,style:s}:void 0),...x})});ae.classes=z;ae.displayName="@mantine/core/InputError";const fe={labelElement:"label"},ao=K((n,{size:o})=>({label:{"--input-label-size":W(o),"--input-asterisk-color":void 0}})),re=E((n,o)=>{const t=w("InputLabel",fe,n),{classNames:i,className:r,style:s,styles:h,unstyled:d,vars:c,labelElement:f,size:l,required:a,htmlFor:p,onMouseDown:u,children:x,__staticSelector:m,variant:y,mod:b,attributes:S,...v}=w("InputLabel",fe,t),I=L({name:["InputWrapper",m],props:t,classes:z,className:r,style:s,classNames:i,styles:h,unstyled:d,attributes:S,rootSelector:"label",vars:c,varsResolver:ao}),D=oe(),A=D?.getStyles||I;return e.jsxs(k,{...A("label",D?.getStyles?{className:r,style:s}:void 0),component:f,variant:y,size:l,ref:o,htmlFor:f==="label"?p:void 0,mod:[{required:a},b],onMouseDown:g=>{u?.(g),!g.defaultPrevented&&g.detail>1&&g.preventDefault()},...v,children:[x,a&&e.jsx("span",{...A("required"),"aria-hidden":!0,children:" *"})]})});re.classes=z;re.displayName="@mantine/core/InputLabel";const me=E((n,o)=>{const t=w("InputPlaceholder",null,n),{classNames:i,className:r,style:s,styles:h,unstyled:d,vars:c,__staticSelector:f,variant:l,error:a,mod:p,attributes:u,...x}=t,m=L({name:["InputPlaceholder",f],props:t,classes:z,className:r,style:s,classNames:i,styles:h,unstyled:d,attributes:u,rootSelector:"placeholder"});return e.jsx(k,{...m("placeholder"),mod:[{error:!!a},p],component:"span",variant:l,ref:o,...x})});me.classes=z;me.displayName="@mantine/core/InputPlaceholder";function ro(n,{hasDescription:o,hasError:t}){const i=n.findIndex(c=>c==="input"),r=n.slice(0,i),s=n.slice(i+1),h=o&&r.includes("description")||t&&r.includes("error");return{offsetBottom:o&&s.includes("description")||t&&s.includes("error"),offsetTop:h}}const so={labelElement:"label",inputContainer:n=>n,inputWrapperOrder:["label","description","input","error"]},lo=K((n,{size:o})=>({label:{"--input-label-size":W(o),"--input-asterisk-color":void 0},error:{"--input-error-size":o===void 0?void 0:`calc(${W(o)} - ${O(2)})`},description:{"--input-description-size":o===void 0?void 0:`calc(${W(o)} - ${O(2)})`}})),he=E((n,o)=>{const t=w("InputWrapper",so,n),{classNames:i,className:r,style:s,styles:h,unstyled:d,vars:c,size:f,variant:l,__staticSelector:a,inputContainer:p,inputWrapperOrder:u,label:x,error:m,description:y,labelProps:b,descriptionProps:S,errorProps:v,labelElement:I,children:D,withAsterisk:A,id:g,required:$,__stylesApiProps:Z,mod:Y,attributes:te,...U}=t,H=L({name:["InputWrapper",a],props:Z||t,classes:z,className:r,style:s,classNames:i,styles:h,unstyled:d,attributes:te,vars:c,varsResolver:lo}),R={size:f,variant:l,__staticSelector:a},P=ve(g),Q=typeof A=="boolean"?A:$,T=v?.id||`${P}-error`,V=S?.id||`${P}-description`,F=P,_=!!m&&typeof m!="boolean",M=!!y,G=`${_?T:""} ${M?V:""}`,X=G.trim().length>0?G.trim():void 0,C=b?.id||`${P}-label`,le=x&&e.jsx(re,{labelElement:I,id:C,htmlFor:F,required:Q,...R,...b,children:x},"label"),q=M&&e.jsx(ie,{...S,...R,size:S?.size||R.size,id:S?.id||V,children:y},"description"),de=e.jsx(j.Fragment,{children:p(D)},"input"),ee=_&&j.createElement(ae,{...v,...R,size:v?.size||R.size,key:"error",id:v?.id||T},m),Pe=u.map(Ie=>{switch(Ie){case"label":return le;case"input":return de;case"description":return q;case"error":return ee;default:return null}});return e.jsx(to,{value:{getStyles:H,describedBy:X,inputId:F,labelId:C,...ro(u,{hasDescription:M,hasError:_})},children:e.jsx(k,{ref:o,variant:l,size:f,mod:[{error:!!m},Y],...H("root"),...U,children:Pe})})});he.classes=z;he.displayName="@mantine/core/InputWrapper";const co={variant:"default",leftSectionPointerEvents:"none",rightSectionPointerEvents:"none",withAria:!0,withErrorStyles:!0,size:"sm"},po=K((n,o,t)=>({wrapper:{"--input-margin-top":t.offsetTop?"calc(var(--mantine-spacing-xs) / 2)":void 0,"--input-margin-bottom":t.offsetBottom?"calc(var(--mantine-spacing-xs) / 2)":void 0,"--input-height":J(o.size,"input-height"),"--input-fz":W(o.size),"--input-radius":o.radius===void 0?void 0:ce(o.radius),"--input-left-section-width":o.leftSectionWidth!==void 0?O(o.leftSectionWidth):void 0,"--input-right-section-width":o.rightSectionWidth!==void 0?O(o.rightSectionWidth):void 0,"--input-padding-y":o.multiline?J(o.size,"input-padding-y"):void 0,"--input-left-section-pointer-events":o.leftSectionPointerEvents,"--input-right-section-pointer-events":o.rightSectionPointerEvents}})),B=ye((n,o)=>{const t=w("Input",co,n),{classNames:i,className:r,style:s,styles:h,unstyled:d,required:c,__staticSelector:f,__stylesApiProps:l,size:a,wrapperProps:p,error:u,disabled:x,leftSection:m,leftSectionProps:y,leftSectionWidth:b,rightSection:S,rightSectionProps:v,rightSectionWidth:I,rightSectionPointerEvents:D,leftSectionPointerEvents:A,variant:g,vars:$,pointer:Z,multiline:Y,radius:te,id:U,withAria:H,withErrorStyles:R,mod:P,inputSize:Q,attributes:T,__clearSection:V,__clearable:F,__defaultRightSection:_,...M}=t,{styleProps:G,rest:X}=ge(M),C=oe(),le={offsetBottom:C?.offsetBottom,offsetTop:C?.offsetTop},q=L({name:["Input",f],props:l||t,classes:z,className:r,style:s,classNames:i,styles:h,unstyled:d,attributes:T,stylesCtx:le,rootSelector:"wrapper",vars:$,varsResolver:po}),de=H?{required:c,disabled:x,"aria-invalid":!!u,"aria-describedby":C?.describedBy,id:C?.inputId||U}:{},ee=oo({__clearable:F,__clearSection:V,rightSection:S,__defaultRightSection:_,size:a});return e.jsx(Qe,{value:{size:a||"sm"},children:e.jsxs(k,{...q("wrapper"),...G,...p,mod:[{error:!!u&&R,pointer:Z,disabled:x,multiline:Y,"data-with-right-section":!!ee,"data-with-left-section":!!m},P],variant:g,size:a,children:[m&&e.jsx("div",{...y,"data-position":"left",...q("section",{className:y?.className,style:y?.style}),children:m}),e.jsx(k,{component:"input",...X,...de,ref:o,required:c,mod:{disabled:x,error:!!u&&R},variant:g,__size:Q,...q("input")}),ee&&e.jsx("div",{...v,"data-position":"right",...q("section",{className:v?.className,style:v?.style}),children:ee})]})})});B.classes=z;B.Wrapper=he;B.Label=re;B.Error=ae;B.Description=ie;B.Placeholder=me;B.ClearButton=Me;B.displayName="@mantine/core/Input";var ke={root:"m_5f75b09e",body:"m_5f6e695e",labelWrapper:"m_d3ea56bb",label:"m_8ee546b8",description:"m_328f68c0",error:"m_8e8a99cc"};const mo=ke,we=j.forwardRef(({__staticSelector:n,__stylesApiProps:o,className:t,classNames:i,styles:r,unstyled:s,children:h,label:d,description:c,id:f,disabled:l,error:a,size:p,labelPosition:u="left",bodyElement:x="div",labelElement:m="label",variant:y,style:b,vars:S,mod:v,attributes:I,...D},A)=>{const g=L({name:n,props:o,className:t,style:b,classes:ke,classNames:i,styles:r,unstyled:s,attributes:I});return e.jsx(k,{...g("root"),ref:A,__vars:{"--label-fz":W(p),"--label-lh":J(p,"label-lh")},mod:[{"label-position":u},v],variant:y,size:p,...D,children:e.jsxs(k,{component:x,htmlFor:x==="label"?f:void 0,...g("body"),children:[h,e.jsxs("div",{...g("labelWrapper"),"data-disabled":l||void 0,children:[d&&e.jsx(k,{component:m,htmlFor:m==="label"?f:void 0,...g("label"),"data-disabled":l||void 0,children:d}),c&&e.jsx(B.Description,{size:p,__inheritStyles:!1,...g("description"),children:c}),a&&typeof a!="boolean"&&e.jsx(B.Error,{size:p,__inheritStyles:!1,...g("error"),children:a})]})]})})});we.displayName="@mantine/core/InlineInput";function ho({children:n,role:o}){const t=oe();return t?e.jsx("div",{role:o,"aria-labelledby":t.labelId,"aria-describedby":t.describedBy,children:n}):e.jsx(e.Fragment,{children:n})}const Be=j.createContext(null),uo=Be.Provider,xo=()=>j.useContext(Be),ue=E((n,o)=>{const{value:t,defaultValue:i,onChange:r,size:s,wrapperProps:h,children:d,readOnly:c,disabled:f,...l}=w("SwitchGroup",null,n),[a,p]=je({value:t,defaultValue:i,finalValue:[],onChange:r}),u=x=>{const m=x.currentTarget.value;!c&&p(a.includes(m)?a.filter(y=>y!==m):[...a,m])};return e.jsx(uo,{value:{value:a,onChange:u,size:s,disabled:f},children:e.jsx(B.Wrapper,{size:s,ref:o,...h,...l,labelElement:"div",__staticSelector:"SwitchGroup",children:e.jsx(ho,{role:"group",children:d})})})});ue.classes=B.Wrapper.classes;ue.displayName="@mantine/core/SwitchGroup";var ze={root:"m_5f93f3bb",input:"m_926b4011",track:"m_9307d992",thumb:"m_93039a1d",trackLabel:"m_8277e082"};const fo={labelPosition:"right",withThumbIndicator:!0},yo=K((n,{radius:o,color:t,size:i})=>({root:{"--switch-radius":o===void 0?void 0:ce(o),"--switch-height":J(i,"switch-height"),"--switch-width":J(i,"switch-width"),"--switch-thumb-size":J(i,"switch-thumb-size"),"--switch-label-font-size":J(i,"switch-label-font-size"),"--switch-track-label-padding":J(i,"switch-track-label-padding"),"--switch-color":t?Te(t,n):void 0}})),se=E((n,o)=>{const t=w("Switch",fo,n),{classNames:i,className:r,style:s,styles:h,unstyled:d,vars:c,color:f,label:l,offLabel:a,onLabel:p,id:u,size:x,radius:m,wrapperProps:y,thumbIcon:b,checked:S,defaultChecked:v,onChange:I,labelPosition:D,description:A,error:g,disabled:$,variant:Z,rootRef:Y,mod:te,withThumbIndicator:U,attributes:H,...R}=t,P=xo(),Q=x||P?.size,T=L({name:"Switch",props:t,classes:ze,className:r,style:s,classNames:i,styles:h,unstyled:d,attributes:H,vars:c,varsResolver:yo}),{styleProps:V,rest:F}=ge(R),_=ve(u),M={checked:P?.value.includes(F.value)??S,onChange:C=>{P?.onChange(C),I?.(C)},disabled:P?.disabled??$},[G,X]=je({value:M.checked??S,defaultValue:v,finalValue:!1});return e.jsxs(we,{...T("root"),__staticSelector:"Switch",__stylesApiProps:t,id:_,size:Q,labelPosition:D,label:l,description:A,error:g,disabled:M.disabled,bodyElement:"label",labelElement:"span",classNames:i,styles:h,unstyled:d,"data-checked":M.checked,variant:Z,ref:Y,mod:te,...V,...y,children:[e.jsx("input",{...F,...M,checked:G,"data-checked":M.checked,onChange:C=>{M.onChange?.(C),X(C.currentTarget.checked)},id:_,ref:o,type:"checkbox",role:"switch",...T("input")}),e.jsxs(k,{"aria-hidden":"true",component:"span",mod:{error:g,"label-position":D,"without-labels":!p&&!a},...T("track"),children:[e.jsx(k,{component:"span",mod:{"reduce-motion":!0,"with-thumb-indicator":U&&!b},...T("thumb"),children:b}),e.jsx("span",{...T("trackLabel"),children:G?p:a})]})]})});se.classes={...ze,...mo};se.displayName="@mantine/core/Switch";se.Group=ue;const go=[["path",{d:"M3 10a7 7 0 1 0 14 0a7 7 0 1 0 -14 0",key:"svg-0"}],["path",{d:"M21 21l-6 -6",key:"svg-1"}]],bo=Ne("outline","search","Search",go),vo="_searchForm_neyvh_1",jo="_left_neyvh_53",So="_right_neyvh_86",N={searchForm:vo,"form-wrap":"_form-wrap_neyvh_5","input-box":"_input-box_neyvh_10","list-header":"_list-header_neyvh_44",left:jo,"list-title":"_list-title_neyvh_58",right:So},Co=[{id:1,title:"Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial",content:e.jsxs("div",{style:{maxWidth:"900px",margin:"0 auto",padding:"16px",backgroundColor:"white",fontFamily:'-apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, sans-serif',color:"#333",lineHeight:"1.5"},children:[e.jsx("h1",{style:{fontSize:"20px",fontWeight:"bold",color:"#1a202c",marginBottom:"16px",lineHeight:"1.3",textDecoration:"none"},children:"Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial"}),e.jsxs("div",{style:{fontSize:"13px",marginBottom:"12px",color:"#4a5568"},children:[e.jsxs("p",{style:{color:"#0071bc"},children:["Meletios A Dimopoulos ",e.jsx("sup",{style:{color:"black",backgroundColor:"#f1f1f1"},children:"1"}),", Evangelos Terpos ",e.jsx("sup",{style:{color:"black",backgroundColor:"#f1f1f1"},children:"2"}),", Mario Boccadoro ",e.jsx("sup",{style:{color:"black",backgroundColor:"#f1f1f1"},children:"3"}),", Sosana Delimpasi ",e.jsx("sup",{style:{color:"black",backgroundColor:"#f1f1f1"},children:"4"}),", Meral Beksac ",e.jsx("sup",{style:{color:"black",backgroundColor:"#f1f1f1"},children:"5"}),", Erini Katodritou ",e.jsx("sup",{style:{color:"black",backgroundColor:"#f1f1f1"},children:"6"}),", Philippe Moreau ",e.jsx("sup",{style:{color:"black",backgroundColor:"#f1f1f1"},children:"7"}),", Luca Baldini ",e.jsx("sup",{style:{color:"black",backgroundColor:"#f1f1f1"},children:"8"}),", Argiris Symeonidis ",e.jsx("sup",{style:{color:"black",backgroundColor:"#f1f1f1"},children:"9"}),", Jelena Bila ",e.jsx("sup",{style:{color:"black",backgroundColor:"#f1f1f1"},children:"10"}),", Alberto Oriol ",e.jsx("sup",{style:{color:"black",backgroundColor:"#f1f1f1"},children:"11"}),", Maria-Victoria Mateos ",e.jsx("sup",{style:{color:"black",backgroundColor:"#f1f1f1"},children:"12"}),", Hermann Einsele ",e.jsx("sup",{style:{color:"black",backgroundColor:"#f1f1f1"},children:"13"}),", Ioannis Orfanidis ",e.jsx("sup",{style:{color:"black",backgroundColor:"#f1f1f1"},children:"14"}),", Tahamtan Ahmadi ",e.jsx("sup",{style:{color:"black",backgroundColor:"#f1f1f1"},children:"15"}),", Jon Kropiec ",e.jsx("sup",{style:{color:"black",backgroundColor:"#f1f1f1"},children:"16"}),", Tobias Kämpfenkel ",e.jsx("sup",{style:{color:"black",backgroundColor:"#f1f1f1"},children:"17"}),", Jordan M Schechter ",e.jsx("sup",{style:{color:"black",backgroundColor:"#f1f1f1"},children:"18"}),", Yanping Qiu ",e.jsx("sup",{style:{color:"black",backgroundColor:"#f1f1f1"},children:"19"}),", Himal Amin ",e.jsx("sup",{style:{color:"black",backgroundColor:"#f1f1f1"},children:"18"}),", Jessica Vermeulen ",e.jsx("sup",{style:{color:"black",backgroundColor:"#f1f1f1"},children:"17"}),", Robin Carson ",e.jsx("sup",{style:{color:"black",backgroundColor:"#f1f1f1"},children:"20"}),", Pieter Sonneveld ",e.jsx("sup",{style:{color:"black",backgroundColor:"#f1f1f1"},children:"21"}),";"]}),e.jsx("p",{style:{fontStyle:"italic",color:"#0071bc"},children:"APOLLO Trial Investigators"})]}),e.jsxs("div",{style:{fontSize:"12px",marginBottom:"12px",color:"#212121"},children:[e.jsx("p",{children:"Collaborators, Affiliations + expand"}),e.jsxs("p",{children:["PMID: 34087126 DOI: ",e.jsx("span",{style:{color:"#2563eb",cursor:"pointer"},children:"10.1016/S1470-2045(21)00128-5"})]})]}),e.jsx("h2",{style:{fontSize:"16px",fontWeight:"bold",color:"#1a202c",marginBottom:"8px",paddingBottom:"4px"},children:"Abstract"}),e.jsxs("div",{style:{marginBottom:"12px"},children:[e.jsx("p",{style:{fontWeight:"bold",display:"inline",marginRight:"4px"},children:"Background:"}),e.jsx("span",{style:{fontSize:"13px"},children:"In a phase 1b study, intravenous daratumumab plus pomalidomide and dexamethasone induced a very good partial response or better rate of 42% and was well tolerated in patients with heavily pretreated multiple myeloma. We aimed to evaluate whether daratumumab plus pomalidomide and dexamethasone would improve progression-free survival versus pomalidomide and dexamethasone alone in patients with previously treated multiple myeloma."})]}),e.jsxs("div",{style:{marginBottom:"12px"},children:[e.jsx("p",{style:{fontWeight:"bold",display:"inline",marginRight:"4px"},children:"Methods:"}),e.jsx("span",{style:{fontSize:"13px"},children:"In this ongoing, open-label, randomised, phase 3 trial (APOLLO) done at 48 academic centres and hospitals across 12 European countries, eligible patients were aged 18 years or older, had relapsed or refractory multiple myeloma with measurable disease, had an Eastern Cooperative Oncology Group performance status of 0-2, had at least one previous line of therapy, including lenalidomide and a proteasome inhibitor, had a partial response or better to one or more previous lines of antimyeloma therapy, and were refractory to lenalidomide if only one previous line of therapy was received. Patients were randomly assigned (1:1) by an interactive web-response system in a random block size of two or four to receive pomalidomide and dexamethasone alone or daratumumab plus pomalidomide and dexamethasone. Randomisation was stratified by number of previous lines of therapy and International Staging System disease stage. All patients received oral pomalidomide (4 mg, once daily on days 1-21) and oral dexamethasone (40 mg once daily on days 1, 8, 15, and 22; 20 mg for those aged 75 years or older) at each 28-day cycle. The daratumumab plus pomalidomide and dexamethasone group received daratumumab (1800 mg subcutaneously or 16 mg/kg intravenously) weekly during cycles 1 and 2, every 2 weeks during cycles 3-6, and every 4 weeks thereafter until disease progression or unacceptable toxicity. The primary endpoint was progression-free survival in the intention-to-treat population. Safety was analysed in all patients who received at least one dose of study medication. This trial is registered with ClinicalTrials.gov, NCT03180736."})]}),e.jsxs("div",{style:{marginBottom:"12px"},children:[e.jsx("p",{style:{fontWeight:"bold",display:"inline",marginRight:"4px"},children:"Findings:"}),e.jsx("span",{style:{fontSize:"13px"},children:"Between June 22, 2017, and June 13, 2019, 304 patients (median age 67 years [IQR 60-72]; 161 [53%] men and 143 [47%] women) were randomly assigned to the daratumumab plus pomalidomide and dexamethasone group (n=151) or the pomalidomide and dexamethasone group (n=153). At a median follow-up of 16·9 months (IQR 14·4-20·6), the daratumumab plus pomalidomide and dexamethasone group showed improved progression-free survival compared with the pomalidomide and dexamethasone group (median 12·4 months [95% CI 8·3-19·3] vs 6·9 months [5·5-9·3]; hazard ratio 0·63 [95% CI 0·47-0·85], two-sided p=0·0018). The most common grade 3 or 4 adverse events were neutropenia (101 [68%] of 149 patients in the daratumumab plus pomalidomide and dexamethasone group vs 75 [56%] of 150 patients in the pomalidomide and dexamethasone group), anaemia (25 [17%] vs 32 [21%]), and thrombocytopenia (25 [17%] vs 27 [18%]). Serious adverse events occurred in 75 (50%) of 149 patients in the daratumumab plus pomalidomide and dexamethasone group versus 59 (39%) of 150 patients in the pomalidomide and dexamethasone group; pneumonia (23 [15%] vs 12 [8%] patients) and lower respiratory tract infection (18 [12%] vs 14 [9%]) were most common. Treatment-emergent deaths were reported in 11 (7%) patients in the daratumumab plus pomalidomide and dexamethasone group versus 11 (7%) patients in the pomalidomide and dexamethasone group."})]}),e.jsxs("div",{style:{marginBottom:"12px"},children:[e.jsx("p",{style:{fontWeight:"bold",display:"inline",marginRight:"4px"},children:"Interpretation:"}),e.jsx("span",{style:{fontSize:"13px"},children:"Among patients with relapsed or refractory multiple myeloma, daratumumab plus pomalidomide and dexamethasone reduced the risk of disease progression or death versus pomalidomide and dexamethasone alone and could be considered a new treatment option in this setting."})]}),e.jsxs("div",{style:{marginBottom:"16px"},children:[e.jsx("p",{style:{fontWeight:"bold",display:"inline",marginRight:"4px"},children:"Funding:"}),e.jsx("span",{style:{fontSize:"13px"},children:"European Myeloma Network and Janssen Research and Development."})]}),e.jsx("div",{style:{fontSize:"12px",color:"#718096",marginBottom:"16px",fontStyle:"italic"},children:"Copyright © 2021 Elsevier Ltd. All rights reserved."}),e.jsx("div",{style:{fontSize:"12px",marginBottom:"24px"},children:e.jsx("a",{href:"#",style:{color:"#2563eb"},children:"PubMed Disclaimer"})}),e.jsx("h2",{style:{fontSize:"16px",fontWeight:"bold",color:"#1a202c",marginBottom:"8px",paddingBottom:"4px"},children:"Conflict of interest statement"}),e.jsx("div",{style:{fontSize:"12px",marginBottom:"24px",lineHeight:"1.4"},children:e.jsx("p",{children:"Declaration of interests MAD received honoraria for participation in advisory boards from Amgen, Takeda, Bristol Myers Squibb, Janssen, and BeiGene. ET received honoraria from Janssen, Genesis, Celgene, and Bristol Myers Squibb; research funding from Janssen and Genesis; and non-financial support from Genesis. MBo received honoraria and research funding from Sanofi, Celgene, Amgen, Janssen, Novartis, and Bristol Myers Squibb; received honoraria from AbbVie; received research funding from Mundipharma; and served on an entity's board of directors or advisory committees for Janssen and GlaxoSmithKline. MBe served as a member on an entity's board of directors or advisory committees, and on a speakers' bureau for Janssen, Sanofi, Amgen, Bristol Myers Squibb, Oncopeptides, and Takeda. EK received honoraria, research funding, personal fees, and non-financial support from Janssen-Cilag. PM served as a consultant for and received honoraria from Celgene/Bristol Myers Squibb, Janssen, Amgen, AbbVie, and Sanofi. AS served on advisory committees and received research funding from Bristol Myers Squibb; served on advisory committees and speakers' bureaus for, and received research funding from, AbbVie, Amgen, Celgene/Genesis, and Sanofi/Genzyme; and received research funding from Astellas. AO served on advisory committees for Celgene/Bristol Myers Squibb, Sanofi, Amgen, and GlaxoSmithKline. M-VM served as a consultant for, received honoraria from, and served on an entity's board of directors or advisory committees for, Janssen, Bristol Myers Squibb/Celgene, Amgen, Takeda, Oncopeptides, GlaxoSmithKline, Sanofi, Pfizer, Regeneron, AbbVie/Genentech, Seattle Genetics, and Adaptive Biotechnologies. HE served as a consultant for, received honoraria and research funding from, and served on a speakers' bureau for Janssen, Celgene, Amgen, GlaxoSmithKline, and Sanofi; and served as a consultant for, received honoraria from, and served on a speakers' bureau for Takeda. TA is an employee of Genmab and is current equity holder in a publicly traded company. JU was an employee of Janssen and equity holder in a publicly traded company at the time of the study, and is currently an employee of Genmab and equity holder in a publicly traded company. TK, JMS, YQ, and RC are employees of Janssen. HA and JV are employees of Janssen and are current equity holders in a publicly traded company. PS received research funding from Amgen, Celgene, Janssen, and Takeda, and received honoraria and served on advisory committees for Janssen, Celgene, Amgen, Takeda, Bristol Myers Squibb, and Skyline Dx. All other authors declare no competing interests."})}),e.jsx("h2",{style:{fontSize:"16px",fontWeight:"bold",color:"#1a202c",marginBottom:"8px",paddingBottom:"4px"},children:"Similar articles"}),e.jsxs("div",{style:{fontSize:"13px",marginBottom:"24px"},children:[e.jsxs("ul",{style:{listStyleType:"none",paddingLeft:"0",margin:0},children:[e.jsxs("li",{style:{marginBottom:"8px"},children:[e.jsx("a",{href:"#",style:{color:"#2563eb"},children:"Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISM): a randomised, open-label, phase 3 trial."}),e.jsx("p",{style:{fontSize:"12px",margin:"2px 0 0 0"},children:"Richardson PG, Oriol A, Beksac M, Liberati AM, Galli M, Schjesvold F, Lindsay J, Weisel K, White D, Facon T, San Miguel J, Sunami K, O'Sorman P, Sonneveld P, Robak P, Semochkin S, Schey S, Yu X, Doerr T, Bensmaina A, Biyukov T, Peluso T, Zokai M, Anderson K, Dimopoulos M; OPTIMMM trial investigators."}),e.jsx("p",{style:{color:"#4D8055"},children:"Lancet Oncol. 2019 Jun;20(6):781-794. doi: 10.1016/S1470-2045(19)30152-4. Epub 2019 May 13. PMID: 31097405    Clinical Trial."})]}),e.jsxs("li",{style:{marginBottom:"8px"},children:[e.jsx("a",{href:"#",style:{color:"#2563eb"},children:"Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial."}),e.jsx("p",{style:{fontSize:"12px",margin:"2px 0 0 0"},children:"Mateos MV, Blacklock H, Schjesvold F, Oriol A, Simpson D, George A, Goldschmidt H, Larocca A, Chanan-Khan A, Sherbenou D, Aviv I, Benyamini N, Iida S, Matsumoto M, Suzuki K, Ribrag V, Usmani SZ, Jagannath S, Ocio E, Rodriguez-Otero P, San Miguel J, Kher U, Farooqui M, Liao J, Marinello P, Lonial S; KEYNOTE-183 Investigators."}),e.jsx("p",{style:{color:"#4D8055"},children:"Lancet Haematol. 2019 Sep;6(9):e459-e469. doi: 10.1016/S2352-3026(19)30110-3. Epub 2019 Jul 18. PMID: 31327687    Clinical Trial."})]}),e.jsxs("li",{style:{marginBottom:"8px"},children:[e.jsx("a",{href:"#",style:{color:"#2563eb"},children:"Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study."}),e.jsx("p",{style:{fontSize:"12px",margin:"2px 0 0 0"},children:"Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study."}),e.jsx("p",{style:{color:"#4D8055"},children:"Lancet Haematol. 2022 Feb;9(2):e98-e110. doi: 10.1016/S2352-3026(21)00381-1. Epub 2022 Jan 12. PMID: 35032434Clinical Trial."})]}),e.jsxs("li",{style:{marginBottom:"8px"},children:[e.jsx("a",{href:"#",style:{color:"#2563eb"},children:"The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use."}),e.jsx("p",{style:{fontSize:"12px",margin:"2px 0 0 0"},children:"Hanaizi Z, Flores B, Hemmings R, Camarero J, Sancho-Lopez A, Salmonson T, Gisselbrecht C, Laane E, Pignatti F."}),e.jsxs("p",{style:{color:"#4D8055"},children:["Oncologist. 2015 Mar;20(3):329-34. doi: 10.1634/theoncologist.2014-0073. Epub 2015 Feb 11. PMID: 25673103    ",e.jsx("span",{style:{color:"#C05600"},children:"Free PMC article."}),"    Review."]})]}),e.jsxs("li",{style:{marginBottom:"8px"},children:[e.jsx("a",{href:"#",style:{color:"#2563eb"},children:"Survival trends using DPd vs. other triplets in early RRMM patients: a population-adjusted indirect treatment comparison."}),e.jsx("p",{style:{fontSize:"12px",margin:"2px 0 0 0"},children:"Anwer F, Lan T, Dolph M, Moradian H, Slaff S, Shih YH, Tang D."}),e.jsxs("p",{style:{color:"#4D8055"},children:["Future Oncol. 2025 Jan;21(2):221-230. doi: 10.1080/14796694.2024.2426443. Epub 2024 Nov 29. PMID: 39611661    ",e.jsx("span",{style:{color:"#C05600"},children:"Free PMC article."})]})]})]}),e.jsx("a",{href:"#",style:{fontSize:"12px",color:"#2563eb"},children:"See all similar articles"})]}),e.jsx("h2",{style:{fontSize:"16px",fontWeight:"bold",color:"#1a202c",marginBottom:"8px",paddingBottom:"4px"},children:"Cited by"}),e.jsxs("div",{style:{fontSize:"13px",marginBottom:"24px"},children:[e.jsxs("ul",{style:{listStyleType:"none",paddingLeft:"0",margin:0},children:[e.jsxs("li",{style:{marginBottom:"8px"},children:[e.jsx("a",{href:"#",style:{color:"#2563eb"},children:"RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma."}),e.jsx("p",{style:{fontSize:"12px",margin:"2px 0 0 0"},children:"Ende-Rajaratnam M, Beck S, Benes V, Salwender H, Bertsch U, Scheid C, Hänel M, Weisel K, Hielscher T, Raab MS, Goldschmidt H, Jauch A, Maes K, De Bruyne E, Menu E, De Veerman D, Vanderkerken K, Seckinger A, Hose D."}),e.jsx("p",{style:{color:"#4D8055"},children:"Front Immunol. 2023 Nov 15;14:1266700. doi: 10.3389/fimmu.2023.1266700. eCollection 2023. PMID: 38085768"})]}),e.jsxs("li",{style:{marginBottom:"8px"},children:[e.jsx("a",{href:"#",style:{color:"#2563eb"},children:"Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma."}),e.jsx("p",{style:{fontSize:"12px",margin:"2px 0 0 0"},children:"Sonneveld P, Zweegman S, Cavo M, Nasserinejad K, Broijl A, Troia R, Pour L, Croockewit S, Corradini P, Patriarca F, Wu K, Droogendijk J, Bos G, Hajek R, Teresa Petrucci M, Ypma P, Zojer N, Minnema MC, Boccadoro M."}),e.jsxs("p",{style:{color:"#4D8055"},children:["Hemasphere. 2022 Sep 30;6(10):e786. doi: 10.1097/HS9.0000000000000786. eCollection 2022 Oct. PMID: 36204691",e.jsx("span",{style:{color:"#C05600"},children:"Free PMC article."})]})]}),e.jsxs("li",{style:{marginBottom:"8px"},children:[e.jsxs("a",{href:"#",style:{color:"#2563eb"},children:["Recent advances in the treatment of multiple myeloma: a brief review. ",e.jsx("span",{style:{color:"#C05600"},children:"Free PMC article."})]}),e.jsx("p",{style:{fontSize:"12px",margin:"2px 0 0 0"},children:"Bobin A, Leleu X."}),e.jsxs("p",{style:{color:"#4D8055"},children:["Fac Rev. 2022 Sep 29;11:28. doi: 10.12703/r/11-28. eCollection 2022. PMID: 36225211 ",e.jsx("span",{style:{color:"#C05600"},children:"Free PMC article."}),e.jsx("span",{style:{color:"#C05600"},children:"Review."})]})]}),e.jsxs("li",{style:{marginBottom:"8px"},children:[e.jsx("a",{href:"#",style:{color:"#2563eb"},children:"Difficult-to-treat patients with relapsed/refractory multiple myeloma: A review of clinical trial results."}),e.jsx("p",{style:{fontSize:"12px",margin:"2px 0 0 0"},children:"Raab MS, Zamagni E, Manier S, Rodriguez-Otero P, Schjesvold F, Broijl A."}),e.jsxs("p",{style:{color:"#4D8055"},children:["EJHaem. 2023 Aug 2;4(4):1117-1131. doi: 10.1002/jha2.743. eCollection 2023 Nov. PMID: 38024633 ",e.jsx("span",{style:{color:"#C05600"},children:"Free PMC article."}),e.jsx("span",{style:{color:"#C05600"},children:"Review."})]})]}),e.jsxs("li",{style:{marginBottom:"8px"},children:[e.jsx("a",{href:"#",style:{color:"#2563eb"},children:"A Broad Learning System to Predict the 28-Day Mortality of Patients Hospitalized with Community-Acquired Pneumonia: A Case-Control Study."}),e.jsx("p",{style:{fontSize:"12px",margin:"2px 0 0 0"},children:"Yuan J, Liu X, Wang WF, Zhang JJ."}),e.jsxs("p",{style:{color:"#4D8055"},children:["Comput Math Methods Med. 2022 Mar 4;2022:7003272. doi: 10.1155/2022/7003272. eCollection 2022. PMID: 35281948 ",e.jsx("span",{style:{color:"#C05600"},children:"Free PMC article."})]})]}),e.jsxs("li",{style:{marginBottom:"8px"},children:[e.jsx("a",{href:"#",style:{color:"#2563eb"},children:"A real-life study of daratumumab-bortezomib-dexamethasone (D-VD) in lenalidomide exposed/refractory multiple myeloma patients: a report from the Triveneto Myeloma Working Group."}),e.jsx("p",{style:{fontSize:"12px",margin:"2px 0 0 0"},children:"Barilà G, Quaglia FM, Furlan A, Pescosta N, Bonalumi A, Marcon C, Pascotta A, Tinelli M, De March E, Lico A, Sartori R, Clissa C, De Sabbata G, Nappi D, Porrazzo M, De Marchi R, Pavan L, Tosetto A, Gherlinzoni F, Krampera M, Bassan R, Patriarca F, Semenzato G, Zambello R."}),e.jsxs("p",{style:{color:"#4D8055"},children:["Ann Hematol. 2024 Jan;103(1):125-132. doi: 10.1007/s00277-023-05443-8. Epub 2023 Sep 20. PMID: 37731147 ",e.jsx("span",{style:{color:"#C05600"},children:"Free PMC article."})]})]})]}),e.jsx("a",{href:"#",style:{fontSize:"12px",color:"#2563eb"},children:'See all "Cited by" articles'})]})]})},{id:2,title:"Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide–sparing pomalidomide–containing triplet regimens for relapsed/refractory multiple myeloma: an indirect treatment comparison",content:e.jsxs("div",{style:{maxWidth:"900px",margin:"0 auto",padding:"16px",backgroundColor:"white",fontFamily:'-apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, sans-serif',color:"#333",lineHeight:"1.5"},children:[e.jsx("h1",{style:{fontSize:"20px",fontWeight:"bold",color:"#1a202c",marginBottom:"16px",lineHeight:"1.3",textDecoration:"none"},children:"Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide–sparing pomalidomide–containing triplet regimens for relapsed/refractory multiple myeloma: an indirect treatment comparison"}),e.jsx("div",{style:{fontSize:"13px",marginBottom:"12px",color:"#4a5568"},children:e.jsxs("p",{style:{color:"#0071bc"},children:["Katja Weisel ",e.jsx("sup",{style:{color:"black",backgroundColor:"#f1f1f1"},children:"1"}),", Meletios A Dimopoulos ",e.jsx("sup",{style:{color:"black",backgroundColor:"#f1f1f1"},children:"2"}),", Meral Beksac ",e.jsx("sup",{style:{color:"black",backgroundColor:"#f1f1f1"},children:"3"}),", Xavier Leleu ",e.jsx("sup",{style:{color:"black",backgroundColor:"#f1f1f1"},children:"4"}),", Joshua Richter ",e.jsx("sup",{style:{color:"black",backgroundColor:"#f1f1f1"},children:"5"}),", Bart Heeg ",e.jsx("sup",{style:{color:"black",backgroundColor:"#f1f1f1"},children:"6"}),", Sachin Patel ",e.jsx("sup",{style:{color:"black",backgroundColor:"#f1f1f1"},children:"7"}),", Istvan Majer ",e.jsx("sup",{style:{color:"black",backgroundColor:"#f1f1f1"},children:"8"}),", Ian McFadden ",e.jsx("sup",{style:{color:"black",backgroundColor:"#f1f1f1"},children:"9"}),", Joseph Mikhael ",e.jsx("sup",{style:{color:"black",backgroundColor:"#f1f1f1"},children:"10"})]})}),e.jsxs("div",{style:{fontSize:"12px",marginBottom:"12px",color:"#212121"},children:[e.jsx("p",{children:"Affiliations + expand"}),e.jsxs("p",{children:["PMID: 38345269 DOI: ",e.jsx("span",{style:{color:"#2563eb",cursor:"pointer"},children:"10.1080/10428194.2023.2300051"})]}),e.jsx("p",{children:e.jsx("span",{style:{color:"#C05600"},children:"Free article"})})]}),e.jsx("h2",{style:{fontSize:"16px",fontWeight:"bold",color:"#1a202c",marginBottom:"8px",paddingBottom:"4px"},children:"Abstract"}),e.jsxs("div",{style:{marginBottom:"16px",fontSize:"13px"},children:[e.jsx("p",{style:{marginBottom:"10px"},children:"Nearly all patients with multiple myeloma eventually relapse or become refractory to treatment. Lenalidomide is increasingly administered in the frontline until disease progression or intolerance to therapy, resulting in the need for highly effective, lenalidomide-sparing options. In this study, carfilzomib plus daratumumab and dexamethasone were evaluated against lenalidomide-sparing, pomalidomide-containing triplets using matching-adjusted indirect comparison in the absence of head-to-head data. The analyses utilized long-term follow-up data from the CANDOR study (NCT03158688)."}),e.jsx("p",{style:{marginBottom:"10px"},children:"Treatment with carfilzomib, daratumumab, and dexamethasone resulted in significantly longer progression-free survival (hazard ratio 0.60 [95% confidence interval: 0.37, 0.88]) vs. pomalidomide plus bortezomib and dexamethasone, and numerically longer progression-free survival (hazard ratio 0.77 [95% confidence interval: 0.50, 1.08]) vs. daratumumab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma and previous lenalidomide exposure, the majority of whom were lenalidomide refractory."}),e.jsx("p",{children:"Carfilzomib plus daratumumab and dexamethasone offers a highly effective, lenalidomide-sparing treatment option for this population."})]}),e.jsxs("div",{style:{fontSize:"13px",marginBottom:"16px",color:"#4a5568"},children:[e.jsx("span",{style:{fontWeight:"bold",marginRight:"4px"},children:"Keywords:"}),e.jsx("span",{children:"Carfilzomib; indirect treatment comparison; lenalidomide-sparing; progression-free survival; relapsed/refractory multiple myeloma."})]}),e.jsx("div",{style:{fontSize:"12px",marginBottom:"24px"},children:e.jsx("a",{href:"#",style:{color:"#2563eb"},children:"PubMed Disclaimer"})}),e.jsx("h2",{style:{fontSize:"16px",fontWeight:"bold",color:"#1a202c",marginBottom:"8px",paddingBottom:"4px"},children:"Similar articles"}),e.jsxs("div",{style:{fontSize:"13px",marginBottom:"24px"},children:[e.jsxs("ul",{style:{listStyleType:"none",paddingLeft:"0",margin:0},children:[e.jsxs("li",{style:{marginBottom:"12px"},children:[e.jsx("a",{href:"#",style:{color:"#2563eb",textDecoration:"none"},children:"Survival trends using DPd vs. other triplets in early RRMM patients: a population-adjusted indirect treatment comparison."}),e.jsx("p",{style:{fontSize:"12px",margin:"2px 0 0 0",color:"#4a5568"},children:"Anwer F, Lan T, Dolph M, Moradian H, Slaff S, Shih YH, Tang D."}),e.jsxs("p",{style:{fontSize:"12px",color:"#4D8055"},children:["Future Oncol. 2025 Jan;21(2):221-230. doi: 10.1080/14796694.2024.2426443. Epub 2024 Nov 29.",e.jsx("br",{}),"PMID: 39611661 ",e.jsx("span",{style:{color:"#C05600"},children:"Free PMC article."})]})]}),e.jsxs("li",{style:{marginBottom:"12px"},children:[e.jsx("a",{href:"#",style:{color:"#2563eb",textDecoration:"none"},children:"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study."}),e.jsx("p",{style:{fontSize:"12px",margin:"2px 0 0 0",color:"#4a5568"},children:"Usmani SZ, Quach H, Mateos MV, Landgren O, Leleu X, Siegel D, Weisel K, Gavriatopoulou M, Oriol A, Rabin N, Nooka A, Qi M, Beksac M, Jakubowiak A, Ding B, Zahtien-Kumeli A, Yusuf A, Dimopoulos M."}),e.jsxs("p",{style:{fontSize:"12px",color:"#4D8055"},children:["Lancet Oncol. 2022 Jan;23(1):65-76. doi: 10.1016/S1470-2045(21)00579-9. Epub 2021 Dec 3.",e.jsx("br",{}),"PMID: 34871550 Clinical Trial."]})]}),e.jsxs("li",{style:{marginBottom:"12px"},children:[e.jsx("a",{href:"#",style:{color:"#2563eb",textDecoration:"none"},children:"Comparative Efficacy of Daratumumab Monotherapy and Pomalidomide Plus Low-Dose Dexamethasone in the Treatment of Multiple Myeloma: A Matching Adjusted Indirect Comparison."}),e.jsx("p",{style:{fontSize:"12px",margin:"2px 0 0 0",color:"#4a5568"},children:"Van Sanden S, Ito T, Diels J, Vogel M, Belch A, Oriol A."}),e.jsxs("p",{style:{fontSize:"12px",color:"#4D8055"},children:["Oncologist. 2018 Mar;23(3):279-287. doi: 10.1634/theoncologist.2017-0103. Epub 2017 Nov 30.",e.jsx("br",{}),"PMID: 29192016 ",e.jsx("span",{style:{color:"#C05600"},children:"Free PMC article."})]})]}),e.jsxs("li",{style:{marginBottom:"12px"},children:[e.jsx("a",{href:"#",style:{color:"#2563eb",textDecoration:"none"},children:"Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial."}),e.jsx("p",{style:{fontSize:"12px",margin:"2px 0 0 0",color:"#4a5568"},children:"Richardson PG, Oriol A, Beksac M, Liberati AM, Galli M, Schjesvold F, Lindsay J, Weisel K, White D, Facon T, San Miguel J, Sunami K, O'Gorman P, Sonneveld P, Robak P, Semochkin S, Schey S, Yu X, Doerr T, Bensmaine A, Biyukov T, Pehuo L, Zaki M, Anderson K, Dimopoulos M; OPTIMISMM trial investigators."}),e.jsxs("p",{style:{fontSize:"12px",color:"#4D8055"},children:["Lancet Oncol. 2019 Jun;20(6):781-794. doi: 10.1016/S1470-2045(19)30152-4. Epub 2019 May 13.",e.jsx("br",{}),"PMID: 31097405 Clinical Trial."]})]}),e.jsxs("li",{style:{marginBottom:"12px"},children:[e.jsx("a",{href:"#",style:{color:"#2563eb",textDecoration:"none"},children:"Carfilzomib in combination with daratumumab in the management of relapsed multiple myeloma."}),e.jsx("p",{style:{fontSize:"12px",margin:"2px 0 0 0",color:"#4a5568"},children:"Touzeau C, Antier C, Moreau P."}),e.jsxs("p",{style:{fontSize:"12px",color:"#4D8055"},children:["Future Oncol. 2021 Mar;17(9):993-998. doi: 10.2217/fon-2020-0907. Epub 2020 Dec 8.",e.jsx("br",{}),"PMID: 33289427 Review."]})]})]}),e.jsx("a",{href:"#",style:{fontSize:"12px",color:"#2563eb"},children:"See all similar articles"})]}),e.jsx("h2",{style:{fontSize:"16px",fontWeight:"bold",color:"#1a202c",marginBottom:"8px",paddingBottom:"4px"},children:"Cited by"}),e.jsxs("div",{style:{fontSize:"13px",marginBottom:"24px"},children:[e.jsxs("ul",{style:{listStyleType:"none",paddingLeft:"0",margin:0},children:[e.jsxs("li",{style:{marginBottom:"12px"},children:[e.jsx("a",{href:"#",style:{color:"#2563eb",textDecoration:"none"},children:"Strengths and Weaknesses of Different Therapeutic Strategies for the Treatment of Patients with Multiple Myeloma Who Progress After the Frontline Use of Lenalidomide: A Narrative Review."}),e.jsx("p",{style:{fontSize:"12px",margin:"2px 0 0 0",color:"#4a5568"},children:"Mele G, Sgherza N, Pastore D, Musto P."}),e.jsxs("p",{style:{fontSize:"12px",color:"#4D8055"},children:["J Clin Med. 2024 Oct 19;13(20):6238. doi: 10.3390/jcm13206238.",e.jsx("br",{}),"PMID: 39458188 ",e.jsx("span",{style:{color:"#C05600"},children:"Free PMC article."})," Review."]})]}),e.jsxs("li",{style:{marginBottom:"12px"},children:[e.jsx("a",{href:"#",style:{color:"#2563eb",textDecoration:"none"},children:"Using protein turnover assay to explore the drug mechanism of Carfilzomib."}),e.jsx("p",{style:{fontSize:"12px",margin:"2px 0 0 0",color:"#4a5568"},children:"Tao Y, Ding X, Jia C, Wang C, Li C."}),e.jsxs("p",{style:{fontSize:"12px",color:"#4D8055"},children:["Acta Biochim Biophys Sin (Shanghai). 2024 Jul 8;57(2):209-222. doi: 10.3724/spbi.424.",e.jsx("br",{}),"PMID: 38978505 ",e.jsx("span",{style:{color:"#C05600"},children:"Free PMC article."})," Review."]})]}),e.jsxs("li",{style:{marginBottom:"12px"},children:[e.jsx("a",{href:"#",style:{color:"#2563eb",textDecoration:"none"},children:"Aggressive Extramedullary Multiple Myeloma Presenting as Small Bowel Obstruction."}),e.jsx("p",{style:{fontSize:"12px",margin:"2px 0 0 0",color:"#4a5568"},children:"Wurtz PJ, McGovern K, Shah J, Stoll KE, Moore D."}),e.jsxs("p",{style:{fontSize:"12px",color:"#4D8055"},children:["J Hematol. 2025 Apr;14(2):86-93. doi: 10.14740/jh2031. Epub 2025 Feb 25.",e.jsx("br",{}),"PMID: 40336918 ",e.jsx("span",{style:{color:"#C05600"},children:"Free PMC article."})," Review."]})]})]}),e.jsx("a",{href:"#",style:{fontSize:"12px",color:"#2563eb"},children:'See all "Cited by" articles'})]})]})},{id:3,title:"Venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed or refractory multiple myeloma (BELLINI): final overall survival results from a randomised, phase 3 study",content:e.jsxs("div",{style:{maxWidth:"900px",margin:"0 auto",padding:"16px",backgroundColor:"white",fontFamily:'-apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, sans-serif',color:"#333",lineHeight:"1.5"},children:[e.jsx("h1",{style:{fontSize:"20px",fontWeight:"bold",color:"#1a202c",marginBottom:"16px",lineHeight:"1.3",textDecoration:"none"},children:"Venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed or refractory multiple myeloma (BELLINI): final overall survival results from a randomised, phase 3 study"}),e.jsx("div",{style:{fontSize:"13px",marginBottom:"12px",color:"#4a5568"},children:e.jsxs("p",{style:{color:"#0071bc"},children:["Shaji K Kumar ",e.jsx("sup",{style:{color:"black",backgroundColor:"#f1f1f1"},children:"1"}),", Simon J Harrison ",e.jsx("sup",{style:{color:"black",backgroundColor:"#f1f1f1"},children:"2"}),", Michele Cavo ",e.jsx("sup",{style:{color:"black",backgroundColor:"#f1f1f1"},children:"3"}),", Javier de la Rubia ",e.jsx("sup",{style:{color:"black",backgroundColor:"#f1f1f1"},children:"4"}),", Rakesh Popat ",e.jsx("sup",{style:{color:"black",backgroundColor:"#f1f1f1"},children:"5"}),", Cristina Gasparetto ",e.jsx("sup",{style:{color:"black",backgroundColor:"#f1f1f1"},children:"6"}),", Vania Hungria ",e.jsx("sup",{style:{color:"black",backgroundColor:"#f1f1f1"},children:"7"}),", Hans Salwender ",e.jsx("sup",{style:{color:"black",backgroundColor:"#f1f1f1"},children:"8"}),", Kenshi Suzuki ",e.jsx("sup",{style:{color:"black",backgroundColor:"#f1f1f1"},children:"9"}),", Inho Kim ",e.jsx("sup",{style:{color:"black",backgroundColor:"#f1f1f1"},children:"10"}),", Maika Onishi ",e.jsx("sup",{style:{color:"black",backgroundColor:"#f1f1f1"},children:"11"}),", Grace Ku ",e.jsx("sup",{style:{color:"black",backgroundColor:"#f1f1f1"},children:"11"}),", Rajvineeth Pothacamury ",e.jsx("sup",{style:{color:"black",backgroundColor:"#f1f1f1"},children:"12"}),", Muhammad Jalaluddin ",e.jsx("sup",{style:{color:"black",backgroundColor:"#f1f1f1"},children:"13"}),", Jiewei Zeng ",e.jsx("sup",{style:{color:"black",backgroundColor:"#f1f1f1"},children:"14"}),", Jeremy A Ross ",e.jsx("sup",{style:{color:"black",backgroundColor:"#f1f1f1"},children:"12"}),", Edyta Dobkowska ",e.jsx("sup",{style:{color:"black",backgroundColor:"#f1f1f1"},children:"13"}),", Philippe Moreau ",e.jsx("sup",{style:{color:"black",backgroundColor:"#f1f1f1"},children:"14"})]})}),e.jsxs("div",{style:{fontSize:"12px",marginBottom:"12px",color:"#212121"},children:[e.jsx("p",{children:"Affiliations + expand"}),e.jsxs("p",{children:["PMID: 40587991 DOI: ",e.jsx("span",{style:{color:"#2563eb",cursor:"pointer"},children:"10.1016/S2352-3026(25)00139-5"})]})]}),e.jsx("h2",{style:{fontSize:"16px",fontWeight:"bold",color:"#1a202c",marginBottom:"8px",paddingBottom:"4px"},children:"Abstract"}),e.jsxs("div",{style:{marginBottom:"16px",fontSize:"13px"},children:[e.jsx("p",{style:{marginBottom:"10px",fontWeight:"bold"},children:"Background:"}),e.jsx("p",{style:{marginBottom:"10px"},children:"The phase 3 BELLINI primary endpoint was met, showing superior progression-free survival with venetoclax versus placebo plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma as assessed by an independent review committee. However, venetoclax showed increased early mortality. Here, we report the final overall survival analysis."}),e.jsx("p",{style:{marginBottom:"10px",fontWeight:"bold"},children:"Methods:"}),e.jsx("p",{style:{marginBottom:"10px"},children:"The randomised, double-blind, multicentre, phase 3 BELLINI study enrolled patients aged 18 years or older with relapsed or refractory multiple myeloma, Eastern Cooperative Oncology Group performance status of 2 or less, and one to three previous therapies, across 90 hospitals in 16 countries. Eligible patients were centrally randomly assigned (2:1, stratified by previous proteasome inhibitor exposure and number of previous lines of therapies) via interactive response technology system (block size 3) to once-daily venetoclax (800 mg orally) or placebo with bortezomib (1-3 mg/m² subcutaneously or intravenously) and dexamethasone (20 mg orally), administered in 21-day cycles for initial eight cycles, followed by 35-day cycles until discontinuation. The primary endpoint was progression-free survival as assessed by an independent review committee in the intention-to-treat population; this analysis reports overall survival and investigator-assessed progression-free survival in the intention-to-treat population. Safety analyses were done in patients who received at least one dose of the study drug. This study is registered with ClinicalTrials.gov (NCT02755597) and is completed."}),e.jsx("p",{style:{marginBottom:"10px",fontWeight:"bold"},children:"Findings:"}),e.jsx("p",{style:{marginBottom:"10px"},children:"From July 19, 2016, to Oct 31, 2017, 291 patients were assigned to venetoclax (n=194) or placebo (n=97); 33 patients (28 in the venetoclax group and five in the placebo group) remained on treatment at the time of this analysis. Of the 291 patients, 152 (52%) were men and 139 (48%) were women. 87 (30%) of 291 patients were Asian, 12 (4%) were Black or African American, 190 (65%) were White, and 32 (11%) were Hispanic or Latino. At 45-6 months (IQR 43-6-48-3) median follow-up, median overall survival was not reached in the venetoclax group (not reached [NR] [95% CI 44-4-not estimable]) or in the placebo group (NR [95% CI 44-0-not estimable]; HR 1-19 [95% CI 0.80-1.77]); p=0-39). Median progression-free survival was 23-4 months (95% CI 16-2-26-4) with venetoclax versus 11-4 months (95% CI 9.5-14.6) with placebo (HR 0-58 [95% CI 0-43-0-78]; p=0-00026). The most common grade 3 or 4 adverse events were thrombocytopenia (51 [26%] of 193 in the venetoclax group vs 38 [40%] of 96 in the placebo group) and neutropenia (58 [30%] of 193 vs eight [8%] of 96 patients). Treatment-related adverse events led to death in four (2%) of 193 patients in the venetoclax group (two patients with pneumonia, one with death, and one with both multiple organ dysfunction syndrome and septic shock) and none in the placebo group."}),e.jsx("p",{style:{marginBottom:"10px",fontWeight:"bold"},children:"Interpretation:"}),e.jsx("p",{children:"Final overall survival analysis in the BELLINI study showed overall survival favouring placebo over venetoclax and progression-free survival favouring venetoclax over placebo, indicating venetoclax usage should be avoided in the general relapsed or refractory multiple myeloma population."})]}),e.jsxs("div",{style:{fontSize:"13px",marginBottom:"16px",color:"#4a5568"},children:[e.jsx("span",{style:{fontWeight:"bold",marginRight:"4px"},children:"Keywords:"}),e.jsx("span",{children:"Venetoclax; bortezomib; dexamethasone; relapsed/refractory multiple myeloma; overall survival; BELLINI trial."})]}),e.jsxs("div",{style:{fontSize:"13px",marginBottom:"16px",color:"#4a5568"},children:[e.jsx("span",{style:{fontWeight:"bold",marginRight:"4px"},children:"Funding:"}),e.jsx("span",{children:"Abbvie and Genentech."})]}),e.jsx("div",{style:{fontSize:"12px",marginBottom:"24px",color:"#666",fontStyle:"italic"},children:e.jsx("p",{children:"Copyright © 2025 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies."})}),e.jsx("div",{style:{fontSize:"12px",marginBottom:"24px"},children:e.jsx("a",{href:"#",style:{color:"#2563eb"},children:"PubMed Disclaimer"})}),e.jsx("h2",{style:{fontSize:"16px",fontWeight:"bold",color:"#1a202c",marginBottom:"8px",paddingBottom:"4px"},children:"Conflict of interest statement"}),e.jsx("div",{style:{fontSize:"13px",marginBottom:"24px",color:"#4a5568"},children:e.jsx("p",{children:"Declaration of interests SKK has grants or contracts from AbbVie, Amgen, Bristol Myers Squibb, Carsgen, GSK, Janssen, Genentech-Roche, Sanofi, Takeda, and Telogenomics; has served as a consultant with no personal payments for AbbVie, Amgen, ArcellX BeiGene, Bristol Myers Squibb, Carsgen, Apizyme, Glycostem, GSK, K36, Menarini, Moderna, Pfizer, Regeneron, Genentech-Roche, Sanofi, Takeda, Telogenomics, Trillium, and Window Therapeutics; has served as a consultant with personal payments for Antengene, Calyx, and CVS Caremark; and has participation on an Independent Review Committee for Oncopeptides. SJH has received grants or contracts paid to institution from Janssen; has received honoraria paid to institution from AbbVie and Janssen; and has participated on a data safety monitoring board or advisory board for Janssen and Karyopharm. JdIR has received payment or honoraria from Amgen, GSK, Johnson & Johnson, and Pfizer; and has received support for attending meetings or travel from Amgen, Johnson & Johnson, and Pfizer. RPop has received grants or contracts from GSK and Pfizer; has received consultancy fees from GSK and Roche; has received payment or honoraria from GSK, AbbVie, Bristol Myers Squibb, Johnson & Johnson, and Pfizer; has received support for attending meetings or travel from GSK and Johnson & Johnson; and has participation on a data safety monitoring board or advisory board for Johnson & Johnson, Galapagos, Sanofi, Roche, and GSK. RPop is supported by the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre. CG has received payment or honoraria from GSK; has served on an advisory board and as a speaker for Janssen, Bristol Myers Squibb, Pfizer, Karyopharm, and Sanofi. VH has received payment or honoraria from AbbVie, Amgen, Bristol Myers Squibb, Janssen, GSK, Pfizer, Sanofi and Takeda. HS has received payment or honoraria from and participated on advisory boards for AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb—Celgene, GSK, Janssen, Oncopeptides, Pfizer, Sanofi, and Stemline; and has received support for attending meetings or travel from Amgen, Bristol Myers Squibb—Celgene, Janssen, and Sanofi. KS has received lecture fees from Takeda, Ono Pharmaceutical, Novartis, Sanofi, Bristol Myers Squibb, and Janssen; and has received advisory fees from special reference laboratories. MO and GK are currently employed by Genentech-Roche and may own stock in Genentech-Roche. RPot, MJ, JZ, JAR, and ED are currently employed by AbbVie and may own AbbVie stock or stock options. PM has received payment or honoraria for advisory boards from AbbVie, Amgen, Celgene-Bristol Myers Squibb, GSK, Janssen, Takeda, Pfizer, and Sanofi. MC and IL declare no competing interests."})}),e.jsx("h2",{style:{fontSize:"16px",fontWeight:"bold",color:"#1a202c",marginBottom:"8px",paddingBottom:"4px"},children:"Similar articles"}),e.jsxs("div",{style:{fontSize:"13px",marginBottom:"24px"},children:[e.jsxs("ul",{style:{listStyleType:"none",paddingLeft:"0",margin:0},children:[e.jsxs("li",{style:{marginBottom:"12px"},children:[e.jsx("a",{href:"#",style:{color:"#2563eb",textDecoration:"none"},children:"Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial."}),e.jsx("p",{style:{fontSize:"12px",margin:"2px 0 0 0",color:"#4a5568"},children:"Hungria V, Robak P, Hus M, Zherebtsova V, Ward C, Ho PI, Hajek R, Kim K, Grosicki S, Sia H, Bryant A, Pitombeira de Lacerda M, Martinez GA, Sureda Balari A, Sandhu I, Cerchione C, Ganly P, Dimopoulos MA, Fu C, Garg M, Abdallah AO, Gatt ME, Oriol Rocafiguera A, Cavo M, Rifkin R, Fujisaki T, Mielnik M, Ficek J, Mantero A, Pirooz N, Varghese S, Lee J, McKeown A, Rogers R, Baig H, Eccersley L, Roy-Ghanta S, Mukhopadhyay P, Nielsen J, Opalinska J, Mateos MV; DREAMM-7 study investigators."}),e.jsxs("p",{style:{fontSize:"12px",color:"#4D8055"},children:["Lancet Oncol. 2025 Aug;26(8):1067-1080. doi: 10.1016/S1470-2045(25)00330-4. Epub 2025 Jul 15.",e.jsx("br",{}),"PMID: 40680754 Clinical Trial."]})]}),e.jsxs("li",{style:{marginBottom:"12px"},children:[e.jsx("a",{href:"#",style:{color:"#2563eb",textDecoration:"none"},children:"Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial."}),e.jsx("p",{style:{fontSize:"12px",margin:"2px 0 0 0",color:"#4a5568"},children:"San-Miguel JF, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Günther A, Nakorn TN, Siritanaratkul N, Corradini P, Chuncharunee S, Lee JJ, Schlossman RL, Shelekhova T, Yong K, Tan D, Numbenjapon T, Cavenagh JD, Hou J, LeBlanc R, Nahi H, Qiu L, Salwender H, Pulini S, Moreau P, Warzocha K, White D, Bladé J, Chen W, de la Rubia J, Gimsing P, Lonial S, Kaufman JL, Ocio EM, Veskovski L, Sohn SK, Wang MC, Lee JH, Einsele H, Sopala M, Corrado C, Bengoudifa BR, Binlich F, Richardson PG."}),e.jsxs("p",{style:{fontSize:"12px",color:"#4D8055"},children:["Lancet Oncol. 2014 Oct;15(11):1195-206. doi: 10.1016/S1470-2045(14)70440-1. Epub 2014 Sep 18.",e.jsx("br",{}),"PMID: 25242045 Clinical Trial."]})]}),e.jsxs("li",{style:{marginBottom:"12px"},children:[e.jsx("a",{href:"#",style:{color:"#2563eb",textDecoration:"none"},children:"Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study."}),e.jsx("p",{style:{fontSize:"12px",margin:"2px 0 0 0",color:"#4a5568"},children:"Wang M, Jurczak W, Trněný M, Belada D, Wróbel T, Ghosh N, Keating MM, van Meerten T, Alvarez RF, von Keudell G, Thieblemont C, Peyrade F, Andre M, Hoffmann M, Szafer-Glusman E, Lin J, Dean JP, Neuenburg JK, Tam CS."}),e.jsxs("p",{style:{fontSize:"12px",color:"#4D8055"},children:["Lancet Oncol. 2025 Feb;26(2):200-213. doi: 10.1016/S1470-2045(24)00682-X.",e.jsx("br",{}),"PMID: 39914418 Clinical Trial."]})]}),e.jsxs("li",{style:{marginBottom:"12px"},children:[e.jsx("a",{href:"#",style:{color:"#2563eb",textDecoration:"none"},children:"Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial."}),e.jsx("p",{style:{fontSize:"12px",margin:"2px 0 0 0",color:"#4a5568"},children:"Richardson PG, Oriol A, Beksac M, Liberati AM, Galli M, Schjesvold F, Lindsay J, Weisel K, White D, Facon T, San Miguel J, Sunami K, O'Gorman P, Sonneveld P, Robak P, Semochkin S, Schey S, Yu X, Doerr T, Bensmaine A, Biyukov T, Peluso T, Zaki M, Anderson K, Dimopoulos M; OPTIMISMM trial investigators."}),e.jsxs("p",{style:{fontSize:"12px",color:"#4D8055"},children:["Lancet Oncol. 2019 Jun;20(6):781-794. doi: 10.1016/S1470-2045(19)30152-4. Epub 2019 May 13.",e.jsx("br",{}),"PMID: 31097405 Clinical Trial."]})]}),e.jsxs("li",{style:{marginBottom:"12px"},children:[e.jsx("a",{href:"#",style:{color:"#2563eb",textDecoration:"none"},children:"Symptomatic progression-free survival as an emerging patient-centered endpoint in multiple myeloma: a secondary analysis of MagnetsiMM-3 trial data."}),e.jsx("p",{style:{fontSize:"12px",margin:"2px 0 0 0",color:"#4a5568"},children:"Kortüm M, Theurich S, Farrell J, Jackson G, Cook G, Cappelleri JC, Ashman O, Neff-Baro S, Gauthier A, Jewiti-Rigondza K, Sidhom A, Chaudhary A, Scheid C."}),e.jsxs("p",{style:{fontSize:"12px",color:"#4D8055"},children:["BMC Cancer. 2025 Aug 8;25(1):1288. doi: 10.1186/s12885-025-14724-6.",e.jsx("br",{}),"PMID: 40781281 ",e.jsx("span",{style:{color:"#C05600"},children:"Free PMC article."})]})]})]}),e.jsx("a",{href:"#",style:{fontSize:"12px",color:"#2563eb"},children:"See all similar articles"})]})]})},{id:4,title:"Redefining Cure in Multiple Myeloma: Are We Chasing a Moving Target?",content:e.jsxs("div",{style:{maxWidth:"900px",margin:"0 auto",padding:"16px",backgroundColor:"white",fontFamily:'-apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, sans-serif',color:"#333",lineHeight:"1.5"},children:[e.jsx("h1",{style:{fontSize:"24px",fontWeight:"bold",color:"#1a202c",marginBottom:"16px",lineHeight:"1.3"},children:"Redefining Cure in Multiple Myeloma: Are We Chasing a Moving Target?"}),e.jsx("div",{style:{fontSize:"14px",marginBottom:"12px",color:"#4a5568"},children:e.jsxs("p",{style:{color:"#0071bc"},children:["Jacob Henry Kitundu ",e.jsx("sup",{style:{color:"black",backgroundColor:"#f1f1f1",padding:"1px 4px",borderRadius:"2px"},children:"1"})," ",e.jsx("sup",{style:{color:"black",backgroundColor:"#f1f1f1",padding:"1px 4px",borderRadius:"2px"},children:"2"})]})}),e.jsxs("div",{style:{fontSize:"12px",marginBottom:"16px",color:"#212121"},children:[e.jsx("p",{style:{margin:"4px 0"},children:"Affiliations + expand"}),e.jsxs("p",{style:{margin:"4px 0"},children:["PMID: 41324097 PMCID: PMC12657616 DOI:",e.jsx("span",{style:{color:"#2563eb",cursor:"pointer",marginLeft:"4px"},children:"10.1002/hsr2.71581"})]})]}),e.jsx("h2",{style:{fontSize:"18px",fontWeight:"bold",color:"#1a202c",marginBottom:"12px",paddingBottom:"4px"},children:"Abstract"}),e.jsxs("div",{style:{marginBottom:"20px",fontSize:"14px"},children:[e.jsxs("p",{style:{marginBottom:"12px"},children:[e.jsx("strong",{children:"Background and aims:"}),' Multiple myeloma (MM), a clonal plasma cell malignancy, remains incurable despite significant therapeutic advances, including novel immunotherapies like chimeric antigen receptor T-cell (CAR-T) therapy and bispecific antibodies. This perspective reevaluates the concept of "cure" in MM, challenging the traditional binary definition of complete disease eradication. The author proposes a dynamic, patient-centric model integrating sustained minimal residual disease (MRD) negativity, functional cure, and quality of life (QoL) to align clinical goals with biological realities.']}),e.jsxs("p",{style:{marginBottom:"12px"},children:[e.jsx("strong",{children:"Methods:"})," This perspective reviews current literature on MM pathophysiology, focusing on intratumoral heterogeneity and bone marrow microenvironment interactions as drivers of therapeutic resistance. It critiques existing cytotoxic and immunomodulatory paradigms and explores emerging strategies, including precision medicine, single-cell genomics, and artificial intelligence (AI)-driven risk stratification, to redefine therapeutic endpoints."]}),e.jsxs("p",{style:{marginBottom:"12px"},children:[e.jsx("strong",{children:"Results:"})," Novel immunotherapies achieve deep responses, with MRD negativity rates approaching 80% in some cohorts; however, relapse remains a significant challenge due to subclonal evolution and dormant MM clones. Current treatment paradigms fail to fully address these biological complexities, necessitating innovative approaches that combine therapies, target resistant clones, and incorporate patient-reported outcomes to balance efficacy with QoL."]}),e.jsxs("p",{style:{marginBottom:"12px"},children:[e.jsx("strong",{children:"Conclusion:"})," Reframing cure as a spectrum rather than an absolute state offers a more realistic framework for MM management. By leveraging precision medicine and integrating QoL considerations, clinicians and researchers can foster durable remissions and improve patient outcomes. This perspective advocates for a paradigm shift, urging the MM community to embrace biological complexity and redefine success in this evolving therapeutic landscape."]})]}),e.jsxs("div",{style:{fontSize:"14px",marginBottom:"20px",color:"#4a5568"},children:[e.jsx("span",{style:{fontWeight:"bold",marginRight:"4px"},children:"Keywords:"}),e.jsx("span",{children:"cure; immunotherapy; machine learning; minimal residual disease; multiple myeloma; precision medicine; proteasome inhibitors; quality of life; single-cell RNA-sequencing."})]}),e.jsx("div",{style:{fontSize:"12px",marginBottom:"20px",color:"#666",padding:"8px",borderRadius:"4px"},children:"© 2025 The Author(s). Health Science Reports published by Wiley Periodicals LLC."}),e.jsx("div",{style:{fontSize:"14px",marginBottom:"24px"},children:e.jsx("a",{href:"#",style:{color:"#2563eb",textDecoration:"none"},children:"PubMed Disclaimer"})}),e.jsx("h2",{style:{fontSize:"18px",fontWeight:"bold",color:"#1a202c",marginBottom:"12px",paddingBottom:"4px"},children:"Conflict of interest statement"}),e.jsx("div",{style:{marginBottom:"24px",fontSize:"14px"},children:e.jsx("p",{children:"The author declares no conflicts of interest."})}),e.jsx("h2",{style:{fontSize:"18px",fontWeight:"bold",color:"#1a202c",marginBottom:"12px",paddingBottom:"4px"},children:"Similar articles"}),e.jsxs("div",{style:{fontSize:"14px",marginBottom:"24px"},children:[e.jsxs("ul",{style:{listStyleType:"none",paddingLeft:"0",margin:0},children:[e.jsxs("li",{style:{marginBottom:"16px",paddingBottom:"16px"},children:[e.jsx("a",{href:"#",style:{color:"#2563eb",textDecoration:"none",fontWeight:"500"},children:"Next-generation immunotherapy in relapsed/refractory multiple myeloma: Strategies to achieve sustained MRD negativity."}),e.jsx("p",{style:{fontSize:"13px",margin:"4px 0 0 0",color:"#4a5568"},children:"Zhu L, Nawaz MA, Zuo Y, Zeng P."}),e.jsxs("p",{style:{fontSize:"12px",color:"#4D8055",margin:"2px 0 0 0"},children:["Crit Rev Oncol Hematol. 2025 Oct;214:104913. doi: 10.1016/j.critrevonc.2025.104913. Epub 2025 Aug 21.",e.jsx("br",{}),"PMID: 40848821 ",e.jsx("strong",{children:"Review."})]})]}),e.jsxs("li",{style:{marginBottom:"16px",paddingBottom:"16px"},children:[e.jsx("a",{href:"#",style:{color:"#2563eb",textDecoration:"none",fontWeight:"500"},children:"Redefining multiple myeloma treatment: Advances, challenges, and future directions in immunotherapy."}),e.jsx("p",{style:{fontSize:"13px",margin:"4px 0 0 0",color:"#4a5568"},children:"Fu C, Zhai Y, Yan L, Jin S, Shang J, Shi X, Wu D."}),e.jsxs("p",{style:{fontSize:"12px",color:"#4D8055",margin:"2px 0 0 0"},children:["Chin Med J (Engl). 2025 Aug 8;138(19):2399-410. doi: 10.1097/CM9.0000000000003655. Online ahead of print.",e.jsx("br",{}),"PMID: 40784898 ",e.jsx("span",{style:{color:"#C05600"},children:"Free PMC article."})]})]}),e.jsxs("li",{style:{marginBottom:"16px",paddingBottom:"16px"},children:[e.jsx("a",{href:"#",style:{color:"#2563eb",textDecoration:"none",fontWeight:"500"},children:"Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy."}),e.jsx("p",{style:{fontSize:"13px",margin:"4px 0 0 0",color:"#4a5568"},children:"Chung C."}),e.jsxs("p",{style:{fontSize:"12px",color:"#4D8055",margin:"2px 0 0 0"},children:["Pharmacotherapy. 2017 Jan;37(1):129-143. doi: 10.1002/phar.1871. Epub 2017 Jan 6.",e.jsx("br",{}),"PMID: 27870103 ",e.jsx("strong",{children:"Review."})]})]}),e.jsxs("li",{style:{marginBottom:"16px",paddingBottom:"16px"},children:[e.jsx("a",{href:"#",style:{color:"#2563eb",textDecoration:"none",fontWeight:"500"},children:"Functional cure and long-term survival in multiple myeloma: how to challenge the previously impossible."}),e.jsx("p",{style:{fontSize:"13px",margin:"4px 0 0 0",color:"#4a5568"},children:"Engelhardt M, Kortüm KM, Goldschmidt H, Merz M."}),e.jsxs("p",{style:{fontSize:"12px",color:"#4D8055",margin:"2px 0 0 0"},children:["Haematologica. 2024 Aug 1;109(8):2420-2435. doi: 10.3324/haematol.2023.283058.",e.jsx("br",{}),"PMID: 38356448 ",e.jsx("span",{style:{color:"#C05600"},children:"Free PMC article."})," ",e.jsx("strong",{children:"Review."})]})]}),e.jsxs("li",{style:{marginBottom:"16px",paddingBottom:"16px"},children:[e.jsx("a",{href:"#",style:{color:"#2563eb",textDecoration:"none",fontWeight:"500"},children:"Current landscape and future prospects of bispecific antibodies in multiple myeloma."}),e.jsx("p",{style:{fontSize:"13px",margin:"4px 0 0 0",color:"#4a5568"},children:"Seeburun S."}),e.jsxs("p",{style:{fontSize:"12px",color:"#4D8055",margin:"2px 0 0 0"},children:["J Egypt Natl Canc Inst. 2025 Dec 29;37(1):80. doi: 10.1186/s43046-025-00336-5.",e.jsx("br",{}),"PMID: 41457136 ",e.jsx("strong",{children:"Review."})]})]})]}),e.jsx("a",{href:"#",style:{fontSize:"14px",color:"#2563eb",textDecoration:"none",fontWeight:"500"},children:"See all similar articles"})]})]})}],Mo=[{title(){return e.jsx("div",{style:{color:"var(--text-muted)"},children:"标题"})},dataIndex:"title",key:"title",render:n=>e.jsx("a",{style:{fontWeight:600,color:"var(--primary)"},children:n})}];function Io(){const[n]=xe.useForm(),[o,t]=j.useState({keyword:""}),[i,r]=j.useState([]),[s,h]=j.useState([]),d=j.useRef({showQuickJumper:!0,hideOnSinglePage:!1,showSizeChanger:!0,current:1,pageSize:10,total:0,size:"default",pageSizeOptions:[10,20,50],locale:{jump_to:"跳转至",items_per_page:"/ 页",page:""},onChange:(l,a)=>{d.current.current=l,d.current.pageSize=a,c()}}),c=()=>{let l=[];const a=o.keyword||"";l=Co.filter(m=>m.title.toLowerCase().includes(a.toLowerCase()));const{current:p,pageSize:u}=d.current,x=l.slice((p-1)*u,p*u);h(x),d.current.total=l.length},f=()=>{d.current.current=1,c()};return j.useEffect(()=>{c()},[]),e.jsxs(e.Fragment,{children:[e.jsx(We,{tile:"文献管理",subTitle:"管理和搜索上传的文献数据"}),e.jsx(ne,{style:{marginTop:"15px"},shadow:"xs",padding:"lg",radius:"md",withBorder:!0,children:e.jsx(xe,{layout:"horizontal",form:n,className:N.searchForm,children:e.jsxs("div",{className:N["form-wrap"],children:[e.jsx("div",{className:N["input-box"],children:e.jsx(Fe,{placeholder:"搜索文献标题、概要或内容",onChange:l=>{t({...o,keyword:l.target.value})},value:o.keyword})}),e.jsx("div",{children:e.jsx(Ee,{leftSection:e.jsx(bo,{size:14}),size:"xs",variant:"default",onClick:f,children:"搜索"})}),e.jsx("div",{style:{marginLeft:"10px"},children:e.jsx(se,{withThumbIndicator:!1,labelPosition:"left",label:e.jsxs("div",{style:{display:"flex",alignItems:"center",columnGap:"3px"},children:[e.jsx("span",{style:{color:"#757575"},children:"PubMed"}),e.jsx(Ge,{style:{color:"#b9b9b9ff"}})]})})})]})})}),e.jsxs(ne,{style:{marginTop:"20px"},withBorder:!0,shadow:"sm",radius:"md",children:[e.jsx(ne.Section,{children:e.jsxs("div",{className:N["list-header"],children:[e.jsx("div",{className:N.left,children:e.jsx("div",{className:N["list-title"],children:"文献管理列表"})}),e.jsxs("div",{className:N.right,children:[e.jsx("span",{children:"共"}),e.jsx("span",{children:d.current.total}),e.jsx("span",{children:"条"})]})]})}),e.jsx(ne.Section,{bg:"var(--surface-alt)",children:e.jsx("div",{className:N["list-content"],children:e.jsx(Oe,{rowKey:"id",columns:Mo,dataSource:s,pagination:d.current,rowClassName:"table-row",expandable:{expandedRowRender:l=>e.jsx("div",{children:l.content}),expandedRowKeys:i,onExpand:(l,a)=>{r(l?[a.id]:[])},columnWidth:70,expandIcon({expanded:l,record:a}){return e.jsx("div",{onClick:()=>{r(p=>p.includes(a.id)?[]:[a.id])},style:{cursor:"pointer"},children:l?e.jsx(Ke,{}):e.jsx(He,{})})}}})})})]})]})}export{Io as default};
